Skip to main content

News

GW Pharmaceuticals announces second positive trial for EPIDIOLEX

Last Updated:

GW Pharmaceuticals has announced positive top-line results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) CV in the treatment of seizures associated with Dravet Syndrome. In this trial, EPIDIOLEX, when added to the patient’s current treatment, achieved the primary endpoint of reduction in convulsive seizures for both dose levels (10 mg/kg per day and 20 mg/kg per day) with high statistical significance compared to placebo.

€13.6m FutureNeuro centre launched by Heather Humphreys

Last Updated:

FutureNeuro, a €13.6 million SFI Research Centre has been launched at RCSI, Dublin today. The Centre aims to translate breakthroughs in understanding of brain structure and function to transform the patient journey for people with neurological diseases.

New research grant to investigate autoimmune epilepsy

Last Updated:

A new research grant has been awarded to  Royal College of Surgeons in Ireland under the 2017/2018 round of the Epilepsy Ireland Research Funding Scheme. This project will again open up new possibilities and most importantly has potential to deliver tangible benefits for patients with autoimmune epilepsy.

New report shows leadership benefits of Epilepsy Specialist Nurses

Last Updated:

A new report by Trinity School of Nursing and Midwifery (Rising to the challenge: Epilepsy Specialist Nurses as leaders of service improvements and change, SENsE study) has again highlighted the importance of Epilepsy Specialist Nurses (ESNs) in five key areas of epilepsy care.

These include:

New paper states sodium valproate risks were known in 1990

Last Updated:

A new study on sodium valproate by two leading British academics reveals that patients should have been informed about the drug’s risks during pregnancy as far back as 1990.

Dr Carl Heneghan and Dr Jeffrey Aronson of the University Of Oxford have published a paper entitled “Sodium valproate: who knew what and when? Cumulative meta-analysis gives extra insights.”

The paper researches various sodium valproate studies in the UK and abroad from 1983 to 2014.

Joe Schmidt makes a surprise appearance at book launch

Last Updated:

Ireland Rugby Coach Joe Schmidt made a surprise appearance along with his wife Kelly at the book launch of 'Beautiful Thoughts For Beautiful Minds' in St Patrick’s Cathedral yesterday evening. Also in attendance was Epilepsy Ireland Patron, Rick O’Shea.

FutureNeuro partners with Ergo to develop eHealth technology

Last Updated:

FutureNeuro, the SFI Research Centre for chronic and rare neurological conditions based at RCSI, has announced its partnership with Irish Cloud solution provider Ergo to enhance crucial eHealth infrastructure in Ireland and provide improved monitoring for people living with epilepsy.

Epilepsy in Irish psychiatric inpatient settings

Last Updated:

A study published in the Irish Medical Journal has found that the prevalence of epilepsy in seven psychiatric inpatient units in Ireland was three times that of general population estimates. The prevalence of epilepsy in the general population is approximately 1% but the study has found that nine of a total of 267 patients (3.4%) in the participating psychiatric inpatient units had a diagnosis of epilepsy.

Valproate warning letters sent out

Last Updated:

The recently established Valproate Response project team have written to all female patients currently taking valproate (Epilim) outlining the risks of the drug in pregnancy and the need to discuss treatment with their medical team. These letters have been sent to 3,500 patients and are due to arrive in the post today or tomorrow.